Research Analysts Offer Predictions for IOVA FY2027 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria expects that the biotechnology company will post earnings of $0.13 per share for the year. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.26). The business had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%.

Several other analysts also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Piper Sandler reduced their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a report on Friday, February 28th. Chardan Capital decreased their target price on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Truist Financial decreased their price target on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their price objective on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Trading Down 0.6 %

Shares of NASDAQ:IOVA opened at $3.54 on Friday. The business has a 50-day moving average price of $5.18 and a 200 day moving average price of $7.85. Iovance Biotherapeutics has a 12-month low of $3.48 and a 12-month high of $15.90. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -2.38 and a beta of 0.93.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AlphaQuest LLC lifted its stake in shares of Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 1,794 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter valued at about $36,000. GF Fund Management CO. LTD. acquired a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at about $47,000. One68 Global Capital LLC acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at approximately $74,000. Finally, Quarry LP purchased a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $74,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.